by Denys Wheatley: ESMO Madrid September 2014. Session Monday 29 September 11.00. PET imaging – Potential, pitfalls, and future directions. Two talks on Hodgkin (HL) and non-Hodgkin lymphoma… read more.
by Denys Wheatley: ESMO Madrid September 2014: Session on Sunday 28 September (poster). Dr Moccia and his group in Bellinzona (Switzerland) report on the marked improvement over 30… read more.
Lugano, Switzerland, 25 July 2014. The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has expressed concern that the proposed EU General… read more.
New research suggests that sedating patients before a nerve block needed to diagnose or treat chronic pain increases costs, risks and unnecessary surgeries, and sedation does nothing to… read more.
A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world’s population live in countries where regulations that aim to… read more.
Discussion of the abstract by Dr Christopher Lieu, MD, Assistant professor at the University of Colorado. Younger patients with colorectal cancer that has spread (metastasised) to other parts… read more.
Discussion of the abstract by Professor Philippe Autier, Vice President, Population Studies, at the International Prevention Research Institute, Lyon, France.
Taken from the European Cancer Congress ( ECCO / ESMO / ESTRO ) from the 27th September – 1st October 2013 in Amsterdam.
17th ECCO – 38th ESMO – 32nd ESTRO – European Cancer Congress, Amsterdam RAI, 27 Sept – 1 Oct 2013. Eribulin represents a novel class of antineoplastic agents… read more.
A review of the presentation by Professor David Cunningham (pictured), London, UK. The risk profile of rectal tumours varies with the position and profile of the disease. David… read more.
A review of the presentation by Dermot O’Toole (pictured), Trinity College, Dublin. The incidence of Neuroendocrine tumours (NETs) has increased in recent years. The incidence is higher in… read more.
Dominik Modest, University Hospital, Grosshadern, Munch, Germany. Overall survival (OS) in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) who received first-line treatment with FOLFIRI plus… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
